New triple therapy targets FLT3-Mutated leukemia in frail patients
NCT ID NCT05520567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of three drugs—gilteritinib, venetoclax, and azacitidine—in people newly diagnosed with a fast-growing form of acute myeloid leukemia (AML) that has a FLT3 gene change. Participants are older or have other health issues that prevent them from receiving standard intensive chemotherapy. The trial has two phases: first, finding the right dose of venetoclax, and then testing that dose in more patients to see how well it works and what side effects occur.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gilteritinib, venetoclax, and azacitidine
What this could lead to
If successful, this combination could offer a new, less intensive treatment option for older or frail patients with FLT3-mutated AML, potentially improving remission rates.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits and risks are not yet fully known. Side effects from the drug combination could be serious, and the treatment may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Nat'l Medical Center
Duarte, California, 91010, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Cancer Institute
Pembroke Pines, Florida, 33028, United States
-
Motefiore-Einstein Center for Cancer Care
The Bronx, New York, 10461, United States
-
Novant Health
Winston-Salem, North Carolina, 27103, United States
-
Ohio State University
Columbus, Ohio, 43210, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Robert H. Lurie Comprehensive Cancer Center
Chicago, Illinois, 61612, United States
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
-
Sarah Cannon Research Institute
Denver, Colorado, 80218, United States
-
The Medical College of Wisconsin- Froedtert Hospital
Milwaukee, Wisconsin, 53226, United States
-
The University of Texas MD
Houston, Texas, 77030, United States
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UCLA Medical Center
Los Angeles, California, 90095, United States
-
Univ. of California - Irvine
Irvine, California, 92697, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Maryland
Baltimore, Maryland, 21201, United States
-
University of Pennsylvania-Abramson CCC-Dept. of Hem Onc
Philadelphia, Pennsylvania, 19104, United States
-
Weill Cornell Medical College
New York, New York, 10065, United States